AMLo Biosciences Ltd. is a venture-capital-backed company based in Newcastle-upon-Tyne, UK. The small team is focussed on the development of prognostic medical devices for specific dermatological cancers. AMLo completed a £1.5 million funding round in November 2020. The company now has the resources to continue the development, and begin commercialisation in the UK, Australia and the US, of its first product. AMBLor® comprises biomarkers that accurately prognose the risk of developing metastatic disease in patients with stage I or II melanoma, enabling clinicians to step down surveillance and investigative strategies in the 85% of people with truly low-risk disease. As an entirely novel product, there is interesting potential for significant change management in dermatology. The development pipeline also includes products for the prognoses of patients with cutaneous and oropharyngeal squamous cell carcinoma.
AMLo now is looking to strengthen its board with an NED who has experience of commercialising diagnostic tests in the US. The ideal candidate also will have:
- Experience of working with CLIA laboratories
- Commercialised dermatology and/or oncology products
- An understanding of US reimbursement systems
Candidates wishing to be considered for this role should send their enquiries and/or CV to the Chairman, Dr Sandy Primrose at email@example.com